Type your tag names separated by a space and hit enter




Trade Name(s)

  • Fulyzaq

Ther. Class.

Pharm. Class.


Symptomatic relief of non-infectious diarrhea in HIV-infected patients currently receiving antiretroviral therapy.


  • A natural product derived from Croton lechleri, a species of flowering plant.
  • Inhibits cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CTFR) chloride ion channels and the calcium-activated chloride channels on luminal membranes of enterocytes. Blocks chloride secretion and water loss by inhibiting chloride channels on the membranes of enterocytes.

Therapeutic Effect(s):

Decreased incidence and severity of diarrhea.


Absorption: Minimal absorption following oral administration.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: Unknown.




Contraindicated in:

  • None noted.

Use Cautiously in:

  • Infectious causes of diarrhea (evaluate and treat prior to use);
  • OB: Use during pregnancy only if clearly needed;
  • Lactation: Breast feeding should be avoided by HIV-infected patients;
  • Pedi: Safe and effective use in children <18 yr has not been established.

Adverse Reactions/Side Effects

CNS: anxiety

EENT: nasopharyngitis

Resp: bronchitis, cough, upper respiratory tract infection

GI: abdominal distention, flatulence, hemorrhoids, nausea, ↑ liver function tests

GU: urinary tract infection

MS: arthralgia, back pain, muscuoloskeletal pain

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Due to minimal systemic absorption, interactions are unlikely.


PO: (Adults) 125 mg twice daily.


Delayed-release tablets: 125 mg


  • Assess for abdominal distention, presence of bowel sounds, and usual pattern of bowel function.
  • Assess color, consistency, and amount of stool produced.

Potential Diagnoses


  • PO: Administer tablets twice daily with or without food. Swallow tablets whole; do not crush, break, or chew.

Patient/Family Teaching

  • Instruct patient to take crofelemer as directed.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Decreased incidence and severity of diarrhea.

crofelemer is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Learn more.


Quiring, Courtney, et al. "Crofelemer." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109834/all/crofelemer.
Quiring C, Sanoski CA, Vallerand AH. Crofelemer. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109834/all/crofelemer. Accessed June 15, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Crofelemer. In Davis's Drug Guide. Available from https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109834/all/crofelemer
Quiring C, Sanoski CA, Vallerand AH. Crofelemer [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 June 15]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109834/all/crofelemer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - crofelemer ID - 109834 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109834/all/crofelemer PB - F.A. Davis Company ET - 16 DB - Anesthesia Central DP - Unbound Medicine ER -